our capabilities

Uniquely integrated formulation, device and development capabilities

We effectively integrate all technologies and disciplines required to deliver an inhaled product.

Learn more

Investors

Share price

Learn more

Latest results

View archive

See all

ANNUAL REPORT 2018

AR18_mockup.png

Annual Report and Accounts for the year ended 31 December 2018

Read more
Vectura news
May 15, 2019, 12:08 PM
Vectura data to be shared at ATS 2019
May 4, 2019, 2:00 PM
Vectura wins US GSK patent litigation and awarded $89.7m in damages by jury
Apr 25, 2019, 9:11 AM
R&D: Transformation frees up more resources for innovation
Mar 26, 2019, 7:05 AM
Vectura reports strong 2018 financial and operational performance
Read more
Investment case
1

Differentiated inhalation development capabilities

2

In-market product cash flow generation

3

Focused R&D strategy with pipeline progression and partnering potential

4

Focus on Operational Excellence

5

Strong cash flow generation and capital discipline

Learn more